Mineralocorticoid Receptor Antagonists in Cardiovascular Disease: Rationale, Evidence & Clinical Practice

Mineralocorticoid Receptor Antagonists in Cardiovascular Disease: Rationale, Evidence & Clinical Practice

The IqHS held a scientific symposium on this Friday, February 24, 2023, at Babylon Rotana Hotel entitled ” Mineralocorticoid Receptor Antagonists in Cardiovascular Disease: Rationale, Evidence & Clinical Practice” presented by Dr Ramzi Tabbalat, MD, FACC, FSCCT, Consultant Interventional Cardiologist, Director of Abdali National Amyloidosis Center and Co – Director of Abdali Comprehensive Hypertension Center and was moderated by prof. Ghazi Farhan Haji, the IqHS president. Dr Tabbalat had discussed the recent advances in Pathophysiology of hyperaldosteronism and its detrimental effect on CVS in patient with heart failure especially HFrEF subclass in addition to the role of aldosterone antagonism with special focus on eplerenon and discussing the recent evidence of its use and its positive benefit in different groups of patients like in DM, CKD, and Hypertension. It was an interactive and fruitful presentation and was welcomed by the audience.

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.